CARGO Therapeutics, Inc. Common Stock (CRGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CARGO Therapeutics, Inc. Common Stock (CRGX) has a cash flow conversion efficiency ratio of -0.326x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-77.38 Million) by net assets ($237.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can CARGO Therapeutics, Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
CARGO Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how CARGO Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CARGO Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CARGO Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Winpac Inc
KQ:097800
|
0.123x |
|
Zhejiang Haiyan Power System Resources Environmental Technology Co. Ltd. A
SHG:688565
|
0.049x |
|
Medeon Biodesign
TWO:6499
|
-0.118x |
|
Cellectis SA
NASDAQ:CLLS
|
-0.260x |
|
Immersion Corporation
NASDAQ:IMMR
|
-0.060x |
|
Titan Mining Corp
TO:TI
|
1.432x |
|
Gipta Ofis Kirtasiye ve Promosyon Ãrünleri Imalat Sanayi A.S.
IS:GIPTA
|
-0.172x |
|
Hana Financial 7 SPAC
KQ:230240
|
-0.070x |
Annual Cash Flow Conversion Efficiency for CARGO Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of CARGO Therapeutics, Inc. Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see CARGO Therapeutics, Inc. Common Stock (CRGX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $360.23 Million | $-139.74 Million | -0.388x | -93.76% |
| 2023-12-31 | $405.39 Million | $-81.16 Million | -0.200x | -124.27% |
| 2022-12-31 | $-35.24 Million | $-29.07 Million | 0.825x | -97.08% |
| 2021-12-31 | $-175.00K | $-4.94 Million | 28.240x | -- |
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution design… Read more